Résumé
Background. The Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN SOS) has been performing active influenza surveillance since 2009 ( ClinicalTrials. gov identifier: NCT01517191). Influenza A and B viruses are identified and characterized using real-time reverse-transcriptase polymerase chain reaction (RT-PCR), and multiplex testing has been performed on a subset of patients to identify other respiratory virus aetiologies. Since both methods can identify influenza A and B, a direct comparison was performed. Methods. Validated real-time RT-PCRs from the World Health Organization (WHO) to identify influenza A and B viruses, characterize influenza A viruses into the H1N1 or H3N2 subtypes and describe influenza B viruses belonging to the Yamagata or Victoria lineages. In a subset of patients, the Seeplex RV15 One-Step ACE Detection assay (RV15) kit was also used for the detection of other respiratory viruses. Results. In total, 1111 nasopharyngeal swabs were tested by RV15 and real-time RT-PCRs for influenza A and B identification and characterization. For influenza A, RV15 showed 98.0 % sensitivity, 100 % specificity and 99.7 % accuracy. The performance characteristics of RV15 were similar for influenza A subtypes H1N1 and H3N2. For influenza B, RV15 had 99.2 % sensitivity, 100 % specificity and 99.8 % accuracy, with similar assay performance being shown for both the Yamagata and Victoria lineages. Conclusions. Overall, the detection of circulating subtypes of influenza A and lineages of influenza B by RV15 was similar to detection by real-time RT-PCR. Multiplex testing with RV15 allows for a more comprehensive respiratory virus surveillance in hospitalized adults, without significantly compromising the reliability of influenza A or B virus detection.
| Langue d'origine | English |
|---|---|
| Pages (de-à) | 256-264 |
| Nombre de pages | 9 |
| Journal | Journal of Medical Microbiology |
| Volume | 69 |
| Numéro de publication | 2 |
| DOI | |
| Statut de publication | Published - 2020 |
Note bibliographique
Funding Information:Influenza virus surveillance was funded by the Public Health Agency of Canada (PHAC) and the Canadian Institutes of Health Research (CIHR), and through a Collaborative Research Agreement between GlaxoSmith-Kline Biologicals SA and the CIRN SOS Network. CIRN and SM provided funding for RV15 testing. The authors received no financial support or other form of compensation related to the development of the manuscript, and were solely responsible for final manuscript content and data interpretation.
Funding Information:
J.L. received research grants from Merck for work outside the study, but no personal payments. T.F.H. and S.A.M. report payments to their institution from the GSK group of companies for the conduct of the study, and payments from Pfizer, Merck, Novartis and Sanofi‐Pasteur outside the submitted work. M.K.A. reports grants from the GSK group of companies, Pfizer and Sanofi, but no personal payments. J.M. reports payments to her institution from the GSK group of companies and Sanofi for her participation in advisory boards. A.P. reports payments from Actelion, Sanofi‐Pasteur and Genentech. J.P. reports payments from the GSK group of companies, Merck, Roche and Synthetic Biologics outside the submitted work. L.V. received research grants from the GSK group of companies, Pfizer, Optimer, Cubist and Merck, and personal fees from Merck, Optimer and Cubist. G.D.S. reports he was external consultant at Business and Decision Life Sciences (on behalf of GSK) at the time of the study, and is currently employed by the GSK group of companies and holds shares in the GSK group of companies. No other conflicts were declared.
Publisher Copyright:
© 2020 The Authors.
ASJC Scopus Subject Areas
- Microbiology
- Microbiology (medical)